Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$79.35 USD
+1.21 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $79.24 -0.11 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Vaxcyte, Inc. (PCVX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$100.00 | $113.00 | $76.00 | 27.98% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Vaxcyte, Inc. comes to $100.00. The forecasts range from a low of $76.00 to a high of $113.00. The average price target represents an increase of 27.98% from the last closing price of $78.14.
Analyst Price Targets (7 )
Broker Rating
Vaxcyte, Inc. currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.11 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 11.11% of all recommendations. A month ago, Strong Buy made up 88.89%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PCVX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
5/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Strong Buy |
3/12/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/28/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
2/28/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 9 |
Average Target Price | $100.00 |
LT Growth Rate | 1.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -1.01 |